Detalles de la búsqueda
1.
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Support Care Cancer
; 30(3): 2455-2465, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779921
2.
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Clin Colorectal Cancer
; 20(4): 318-325, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34380594
3.
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Cancers (Basel)
; 12(5)2020 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32429380
4.
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial.
Int J Radiat Oncol Biol Phys
; 93(2): 303-12, 2015 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26031368
Resultados
1 -
4
de 4
1
Próxima >
>>